Results 211 to 220 of about 31,440 (256)
Some of the next articles are maybe not open access.
RCSB Protein Data Bank
ABSTRACT Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used in primary care for diabetes, obesity, and other conditions, offering glycemic control, weight loss, and cardioprotection. This article explores the indications, benefits, risks, and prescribing considerations of GLP-1RAs for nurse practitioners (NPs ...
Clifford J. Rosen, Julie R. Ingelfinger
+8 more sources
ABSTRACT Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used in primary care for diabetes, obesity, and other conditions, offering glycemic control, weight loss, and cardioprotection. This article explores the indications, benefits, risks, and prescribing considerations of GLP-1RAs for nurse practitioners (NPs ...
Clifford J. Rosen, Julie R. Ingelfinger
+8 more sources
GLP-1 receptor agonists in NAFLD
Diabetes & Metabolism, 2017Non-alcoholic fatty liver disease (NAFLD) is very common in patients with type 2 diabetes (T2D), with approximately two-thirds having a diagnosis of the disease. Currently, the only validated treatment for NAFLD is weight loss. A number of studies of animal models and human trials have evaluated the effects of glucagon-like peptide-1 receptor agonists (
Petit, Jean-Michel, Vergès, Bruno
openaire +2 more sources
Emerging GLP-1 receptor agonists
Expert Opinion on Emerging Drugs, 2011Recently, glucagon-like peptide-1 receptor (GLP-1R) agonists have become available for the treatment of type 2 diabetes. These agents exploit the physiological effects of GLP-1, which is able to address several of the pathophysiological features of type 2 diabetes.
Lund, Asger +2 more
openaire +3 more sources
Diabetes Research and Clinical Practice, 2011
Type 2 diabetes mellitus (T2DM) is a complex, progressive disease affecting an estimated 257 million people worldwide. A number of unmet needs exist with traditional T2DM therapies, which can lead to insufficient glycaemic control and increased risk of diabetes-associated complications.
Michel, Marre, Alfred, Penfornis
openaire +2 more sources
Type 2 diabetes mellitus (T2DM) is a complex, progressive disease affecting an estimated 257 million people worldwide. A number of unmet needs exist with traditional T2DM therapies, which can lead to insufficient glycaemic control and increased risk of diabetes-associated complications.
Michel, Marre, Alfred, Penfornis
openaire +2 more sources
The Diabetes Educator, 2015
Purpose Type 2 diabetes (T2D) imparts an increased risk of adverse health outcomes in patients unable to achieve glycemic control. Patient education and individualization of treatment are important for effective management of T2D.
Curtis, Triplitt +1 more
openaire +2 more sources
Purpose Type 2 diabetes (T2D) imparts an increased risk of adverse health outcomes in patients unable to achieve glycemic control. Patient education and individualization of treatment are important for effective management of T2D.
Curtis, Triplitt +1 more
openaire +2 more sources
Novel GLP-1 receptor agonists for diabetes
Expert Opinion on Investigational Drugs, 2011GLP-1 receptor agonists have been shown to be effective in the treatment of type 2 diabetes mellitus (T2DM). Although the first GLP-1 receptor agonist, exenatide, was approved in the mid-2000s, other agents with longer durations of action (that do not require twice-daily dosing) are now being developed.
openaire +2 more sources
Albiglutide: a unique GLP-1 receptor agonist
Expert Opinion on Biological Therapy, 2016Albiglutide is a long acting GLP-1 receptor agonist (GLP-1 RA) administered by weekly injection. Area covered: The pharmacokinetic and pharmacodynamic properties of albiglutide and its clinical effects are discussed. The review encompassed a search of PubMed and a thorough analysis of the European Union and US Food and Drug Administration approval ...
openaire +2 more sources
Gastrointestinal Motility Effects of GLP-1 Receptor Agonists
Current Gastroenterology ReportsThis review summarizes the current understanding of the physiologic influence of GLP-1 RAs on gastrointestinal motility, highlights key clinical implications of these effects, and defines areas for future investigation.Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have revolutionized the treatment of diabetes and obesity and are increasingly ...
Danielle Bellavance +2 more
openaire +2 more sources
Effect of GLP-1 receptor agonists on body composition
Current Opinion in Endocrinology, Diabetes & ObesityPurpose of review Obesity is present in up to 85% of individuals with type 2 diabetes mellitus (T2DM) and poses a major therapeutic challenge. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), initially developed for T2DM, are now widely used for obesity management and increasingly recognized for their ...
Akhila, Bhandarkar +2 more
openaire +2 more sources
Neoadjuvant GLP-1 Receptor Agonists in Sleep Surgery
JAMA Otolaryngology–Head & Neck SurgeryThis Viewpoint examines the potential role of neoadjuvant and adjuvant glucagon-like peptide–1 (GLP-1) receptor agonist therapy in improving surgical outcomes for patients with obstructive sleep apnea and obesity.
Ryan Chin Taw, Cheong, Kenny Peter, Pang
openaire +2 more sources